Keywords
How to Cite
Abstract
Advances in breast cancer treatment in recent years have significantly improved the overall survival of patients. The long-term quality of life of this group of patients, which is inevitably affected by late complications of previous hormone therapy and chemotherapy, is of paramount importance.
Some of the most common late complications of breast cancer treatment, experienced by up to 40 % of patients, are general weakness (asthenia), cognitive impairment and peripheral neuropathy. In most cases, these complications resolve on their own 2 years after the end of treatment, but in some situations they can last longer. The risk of myeloproliferative diseases in patients receiving chemotherapy is 4.6 times higher than in the general population, and the time of onset can vary from 1 to 5 years. This review examines the mechanisms, diagnosis, prevention and treatment of late complications of chemotherapy and hormone therapy for breast cancer, such as general weakness, cognitive impairment, peripheral neuropathy and treatment-related myeloproliferative diseases. The presence of late complications and the need to correct them determine the need for a comprehensive multimodal personalised approach to their prevention and therapy, allowing the stabilisation of remission and improvement of the quality of life of patients.
References
Kohler B.A., Sherman R.L., Howlader N., et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015; 107(6): djv048.-DOI: https://doi.org/10.1093/jnci/djv048.
Ruiz-Casado A., Álvarez-Bustos A., de Pedro C.G., et al. Cancer-related fatigue in breast cancer survivors: a review. Clin Breast Cancer. 2021; 21(1): 10-25.-DOI: https://doi.org/10.1016/j.clbc.2020.07.011.
Servaes P., Verhagen S., Bleijenberg G. Determinants of chronic fatigue in disease-free breast cancer patients: a cross-sectional study. Ann Oncol. 2002; 13(4): 589-598.-DOI: https://doi.org/10.1093/annonc/mdf082.
Bower J.E., Ganz P.A., Desmond K.A., et al. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer. 2006; 106(4): 751-758.-DOI: https://doi.org/10.1002/cncr.21671.
Лукошкина Е.П., Караваева Т.А., Васильева А.В. Этиология, эпидемиология и психотерапия сопутствующих психических расстройств при онкологических заболеваниях. Вопросы онкологии. 2016; 62(6): 774-782. [Lukoshkina E.P., Karavaeva T.A., Vasilieva A.V. Etiology, epidemiology and psychotherapy of concomitant mental disorders in oncological diseases. Voprosy Onkologii = Problems in Oncology. 2016; 62(6): 774-782. (In Rus)].
Bower J.E. The role of neuro-immune interactions in cancer-related fatigue: Biobehavioral risk factors and mechanisms. Cancer. 2019; 125(3): 353-364.-DOI: https://doi.org/10.1002/cncr.31790.
Gielissen M.F., Schattenberg A.V., Verhagen C.A., et al. Experience of severe fatigue in long-term survivors of stem cell transplantation. Bone Marrow Transplant. 2007; 39(10): 595-603.-DOI: https://doi.org/10.1038/sj.bmt.1705624.
Wang T., Yin J., Miller A.H., et al. A systematic review of the association between fatigue and genetic polymorphisms. Brain Behav Immun. 2017; 62: 230-244.-DOI: https://doi.org/10.1016/j.bbi.2017.01.007.
Scuric Z., Carroll J.E., Bower J.E., et al. Biomarkers of aging associated with past treatments in breast cancer survivors. NPJ Breast Cancer. 2017; 3: 50.-DOI: https://doi.org/10.1038/s41523-017-0050-6.
National Comprehensive Cancer Network (NCCN), NCCN clinical practice guidelines in oncology: cancer-related fatigue. NCCN, Version 2.2024. URL: https://www.nccn.org/guidelines.
Fabi A., Bhargava R., Fatigoni S., et al. Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment. Ann Oncol. 2020; 31(6): 713-723.-DOI: https://doi.org/10.1016/j.annonc.2020.02.016.
Vagnini D., Natalucci V., Moi S., et al. Home-based lifestyle intervention for breast cancer survivors: A surprising improvement in the quality of life during the first year of COVID-19 pandemic. PLoS One. 2024; 19(1): e0296163.-DOI: https://doi.org/10.1371/journal.pone.0296163.
Soriano-Maldonado A., Díez-Fernández D.M., Esteban-Simón A., et al. Effects of a 12-week supervised resistance training program, combined with home-based physical activity, on physical fitness and quality of life in female breast cancer survivors: the EFICAN randomized controlled trial. J Cancer Surviv. 2023; 17(5): 1371-1385.-DOI: https://doi.org/10.1007/s11764-022-01192-1.
Kröz M., Quittel F., Reif M., et al. Four-year follow-up on fatigue and sleep quality of a three-armed partly randomized controlled study in breast cancer survivors with cancer-related fatigue. Sci Rep. 2023; 13(1): 2705.-DOI: https://doi.org/10.1038/s41598-022-25322-y.
Pagola I., Morales J.S., Alejo L.B., et al. Concurrent Exercise Interventions in Breast Cancer Survivors with Cancer-related Fatigue. Int J Sports Med. 2020; 41(11): 790-797.-DOI: https://doi.org/10.1055/a-1147-1513.
Kinkead B., Schettler P.J., Larson E.R., et al. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. Cancer. 2018; 124(3): 546-554.-DOI: https://doi.org/10.1002/cncr.31064.
Abrahams H.J.G., Gielissen M.F.M., Donders R.R.T., et al. The efficacy of Internet-based cognitive behavioral therapy for severely fatigued survivors of breast cancer compared with care as usual: A randomized controlled trial. Cancer. 2017; 123(19): 3825-3834.-DOI: https://doi.org/10.1002/cncr.30815.
Zick S.M., Colacino J., Cornellier M., et al. Fatigue reduction diet in breast cancer survivors: a pilot randomized clinical trial. Breast Cancer Res Treat. 2017; 161(2): 299-310.-DOI: https://doi.org/10.1007/s10549-016-4070-y.
Zick S.M., Sen A., Wyatt G.K., et al. Investigation of 2 types of self-administered acupressure for persistent cancer-related fatigue in breast cancer survivors: a randomized clinical trial. JAMA Oncol. 2016; 2(11): 1470-1476.-DOI: https://doi.org/10.1001/jamaoncol.2016.1867.
Bower J.E., Crosswell A.D., Stanton A.L., et al. Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer. 2015; 121(8): 1231-1240.-DOI: https://doi.org/10.1002/cncr.29194.
Lengacher C.A., Reich R.R., Paterson C.L., et al. A large randomized trial: effects of mindfulness-based stress reduction (MBSR) for breast cancer (BC) survivors on salivary cortisol and IL-6. Biol Res Nurs. 2019; 21(1): 39-49.-DOI: https://doi.org/10.1177/1099800418789777.
Das A., Ranadive N., Kinra M., et al. An overview on chemotherapy-induced cognitive impairment and potential role of antidepressants. Curr Neuropharmacol. 2020; 18(9): 838-851.-DOI: https://doi.org/10.2174/1570159X18666200221113842.
Seigers R., Schagen S.B., Van Tellingen O., et al. Chemotherapy-associated cognitive dysfunction: current animal studies and future directions. Brain Imaging Behav. 2013; 7(4): 453-459.-DOI: https://doi.org/10.1007/s11682-013-9250-3.
Janelsins M.C., Heckler C.E., Peppone L.J., et al. Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol. 2017; 35(5): 506-514.-DOI: https://doi.org/10.1200/JCO.2016.68.5826.
Ahles T.A., Saykin A.J., McDonald B.C., et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010; 28(29): 4434-4440.-DOI: https://doi.org/10.1200/JCO.2009.27.0827.
Koppelmans V., Breteler M.M., Boogerd W., et al. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012; 30(10): 1080-6.-DOI: https://doi.org/10.1200/JCO.2011.37.0189.
Mordente A., Meucci E., Silvestrini A., et al. Anthracyclines and mitochondria. Adv Exp Med Biol. 2012; 942: 385-419.-DOI: https://doi.org/10.1007/978-94-007-2869-1_18.
Hernández-Zimbrón L.F., Rivas-Arancibia S. Oxidative stress caused by ozone exposure induces β-amyloid 1-42 overproduction and mitochondrial accumulation by activating the amyloidogenic pathway. Neuroscience. 2015; 304: 340-348.-DOI: https://doi.org/10.1016/j.neuroscience.2015.07.011
Henderson V.W. Menopause and disorders of the central nervous system. Minerva Ginecol. 2005; 57(6): 579-592. URL: https://www.scopus.com/record/display.uri?eid=2-s2.0-29444434719&origin=inward&txGid=d9900ffaa81bae783f0f23344e3a6ffe.
de Ruiter M.B., Reneman L., Kieffer J.M., et al. Brain white matter microstructure as a risk factor for cognitive decline after chemotherapy for breast cancer. J Clin Oncol. 2021; 39(35): 3908-3917.-DOI: https://doi.org/10.1200/JCO.21.00627.
Harrison R.A., Rao V., Kesler S.R. The association of genetic polymorphisms with neuroconnectivity in breast cancer patients. Sci Rep. 2021; 11(1): 6169.-DOI: https://doi.org/10.1038/s41598-021-85768-4.
Lange M., Joly F. How to identify and manage cognitive dysfunction after breast cancer treatment. J Oncol Pract. 2017; 13(12): 784-790.-DOI: https://doi.org/10.1200/JOP.2017.026286.
Караваева Т.А., Васильева А.В., Семиглазова Т.Ю. Психотерапия в онкологии. Психотерапия: национальное руководство. 2023; 939-954. [Karavaeva T.A., Vasilieva A.V., Semiglazova T.Yu. Psychotherapy in oncology. Psychotherapy: national guidelines. 2023; 939-954. (In Rus)].
Lawrence J.A., Griffin L., Balcueva E.P., et al. A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. J Cancer Surviv. 2016; 10(1): 176-184.-DOI: https://doi.org/10.1007/s11764-015-0463-x.
Bandos H., Melnikow J., Rivera D.R., et al. Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG oncology/NSABP B-30. J Natl Cancer Inst. 2018; 110(2): djx162.-DOI: https://doi.org/10.1093/jnci/djx162.
Gärtner R., Jensen M.B., Nielsen J., et al. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009; 302(18): 1985-92.-DOI: https://doi.org/10.1001/jama.2009.1568.
Rivera D.R., Ganz P.A., Weyrich M.S., et al. Chemotherapy-associated peripheral neuropathy in patients with early-stage breast cancer: a systematic review. J Natl Cancer Inst. 2018; 110(2): djx140.-DOI: https://doi.org/10.1093/jnci/djx140.
Grisold W., Cavaletti G., Windebank A.J. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012; 14 Suppl 4(Suppl 4): iv45-iv54.-DOI: https://doi.org/10.1093/neuonc/nos203.
LaPointe N.E., Morfini G., Brady S.T., et al. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology. 2013; 37: 31-239.-DOI: https://doi.org/10.1016/j.neuro.2013.05.008.
Schneider B.P., Li L, Radovich M., et al. genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res. 2015; 21(22): 5082-5091.-DOI: https://doi.org/10.1158/1078-0432.CCR-15-0586.
Chen C.S., Zirpoli G., Barlow W.E., et al. Vitamin D insufficiency as a risk factor for paclitaxel-induced peripheral neuropathy in SWOG S0221. J Natl Compr Canc Netw. 2023; 21(11): 1172-1180.e3.-DOI: https://doi.org/10.6004/jnccn.2023.7062.
Каспаров Б.С., Ковлен Д.В., Семиглазова Т.Ю., et al. Комплексный анализ эффективности персонализированных программ реабилитации больных раком молочной железы. Вопросы курортологии, физиотерапии и лечебной физической культуры. 2023; 100(2): 31-38.-DOI: https://doi.org/10.17116/kurort202310002131. [Kasparov B.S., Kovlen D.V., Semiglazova T.Yu., et al. Comprehensive analysis of the efficacy of personalized rehabilitation programs in patients with breast cancer. Voprosy Kurortologii, Fizioterapii i Lechebnoi Fizicheskoi Kul’tury = Problems of Balneology, Physiotherapy and Exercise Therapy. 2023; 100(2): 31.-DOI: https://doi.org/10.17116/kurort202310002131. (In Rus)].
Латипова Д.Х., Андреев В.В., Маслова Д.А., et al. Неврологические осложнения противоопухолевой лекарственной терапии. Практические рекомендации RUSSCO, часть 2. Злокачественные опухоли. 2023; (13)#3s2: 300-309. URL: https://rosoncoweb.ru/standarts/RUSSCO/2023/2023-56.pdf. [Latipova D.H., Andreyev V.V., Maslova D.A., et al. Neurological complications of antitumour drug therapy. RUSSCO Practice Guidelines, Part 2. Malignant Tumours. 2023; (13)#3s2: 300-309. URL: https://rosoncoweb.ru/standarts/RUSSCO/2023/2023-56.pdf. (In Rus)].
Smith E.M., Pang H., Cirrincione C., et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013; 309(13): 1359-1367.-DOI: https://doi.org/10.1001/jama.2013.2813.
Kautio A.L., Haanpää M., Saarto T., et al. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage. 2008; 35(1): 31-39.-DOI: https://doi.org/10.1016/j.jpainsymman.2007.02.043.
Nihei S., Sato J., Kashiwaba M., et al. Gan To Kagaku Ryoho. 2013; 40(9): 1189-1193. URL: https://www.pieronline.jp/content/article/0385-0684/40090/1189.
Meier T., Wasner G., Faust M., et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain. 2003; 106(1-2): 151-158.-DOI: https://doi.org/10.1016/s0304-3959(03)00317-8.
Anand P., Elsafa E., Privitera R., et al. Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification. J Pain Res. 2019; 12: 2039-2052.-DOI: https://doi.org/10.2147/JPR.S213912.
Fallon M.T., Storey D.J., Krishan A., et al. Cancer treatment-related neuropathic pain: proof of concept study with menthol--a TRPM8 agonist. Support Care Cancer. 2015; 23(9): 2769-2777.-DOI: https://doi.org/10.1007/s00520-015-2642-8.
Prinsloo S., Novy D., Driver L, et al. The long-term impact of neurofeedback on symptom burden and interference in patients with chronic chemotherapy-induced neuropathy: analysis of a randomized controlled trial. J Pain Symptom Manage. 2018; 55(5): 1276-1285.-DOI https://doi.org/10.1016/j.jpainsymman.2018.01.010.
Kneis S., Wehrle A., Müller J., et al. It's never too late - balance and endurance training improves functional performance, quality of life, and alleviates neuropathic symptoms in cancer survivors suffering from chemotherapy-induced peripheral neuropathy: results of a randomized controlled trial. BMC Cancer. 2019; 19(1): 414.-DOI: https://doi.org/10.1186/s12885-019-5522-7.
Han X., Wang L., Shi H., et al. Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma. BMC Cancer. 2017; 17(1): 40.-DOI: https://doi.org/10.1186/s12885-016-3037-z.
Stringer J., Ryder W.D., Mackereth P.A., et al. A randomised, pragmatic clinical trial of ACUpuncture plus standard care versus standard care alone FOr Chemotherapy Induced peripheral Neuropathy (ACUFOCIN). Eur J Oncol Nurs. 2022; 60: 102171.-DOI: https://doi.org/10.1016/j.ejon.2022.102171.
Noh G.O., Park K.S. Effects of aroma self-foot reflexology on peripheral neuropathy, peripheral skin temperature, anxiety, and depression in gynaecologic cancer patients undergoing chemotherapy: A randomised controlled trial. Eur J Oncol Nurs. 2019; 42: 82-89.-DOI: https://doi.org/10.1016/j.ejon.2019.08.007.
Morton L.M., Dores G.M., Tucker M.A., et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood. 2013; 121(15): 2996-3004.-DOI: https://doi.org/10.1182/blood-2012-08-448068.
Matesich S.M., Shapiro C.L. Second cancers after breast cancer treatment. Semin Oncol. 2003; 30(6): 740-748.-DOI: https://doi.org/10.1053/j.seminoncol.2003.08.022.
Smith R.E., Bryant J., DeCillis A., et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol. 2003; 21(7): 1195-1204.-DOI: https://doi.org/10.1200/JCO.2003.03.114.
Taylor C., Correa C., Duane F.K., et al. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol. 2017; 35(15): 1641-1649.-DOI: https://doi.org/10.1200/JCO.2016.72.0722.
Patt D.A., Duan Z., Fang S., et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol. 2007; 25(25): 3871-3876.-DOI: https://doi.org/10.1200/JCO.2007.12.0832.
Schaapveld M., Visser O., Louwman M.J., et al. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol. 2008; 26(8): 1239-1246.-DOI: https://doi.org/10.1200/JCO.2007.11.9081.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2024